Vera Therapeutics, Inc. Operating Lease, Payments
Vera Therapeutics, Inc. (VERA) reported Operating Lease, Payments of $2.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-26
- Vera Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $30.00K, a 95.92% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $759.00K, a 8.44% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, payments for the quarter ending 2025-06-30 was $718.00K, a 8.88% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, payments for the quarter ending 2025-03-31 was $634.00K, a 17.02% decline year-over-year.
- Vera Therapeutics, Inc. operating lease, payments for fiscal 2025 was $2.14M, a 31.29% decline from fiscal 2024.
- Vera Therapeutics, Inc. operating lease, payments for fiscal 2024 was $3.12M, a 3.87% increase from fiscal 2023.
- Vera Therapeutics, Inc. operating lease, payments for fiscal 2023 was $3.00M, a 9.73% increase from fiscal 2022.
- Vera Therapeutics, Inc. operating lease, payments for fiscal 2022 was $2.73M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 9 month as first filed | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $789.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.51M derived: sum of 3 quarters · filed 2026-02-26 | $2.14M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $759.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.48M derived: sum of 2 quarters · filed 2025-11-05 | $2.11M 10-Q · filed 2025-11-05 | $2.85M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2025-06-30 | $718.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.35M 10-Q · filed 2025-08-05 | $2.09M derived: sum of 3 quarters · filed 2026-02-26 | $2.92M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2025-03-31 | $634.00K 10-Q · filed 2025-05-07 | $1.37M derived: sum of 2 quarters · filed 2026-02-26 | $2.20M derived: sum of 3 quarters · filed 2026-02-26 | $2.99M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-12-31 | $735.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.56M derived: sum of 2 quarters · filed 2026-02-26 | $2.35M derived: sum of 3 quarters · filed 2026-02-26 | $3.12M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $829.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.62M derived: sum of 2 quarters · filed 2025-11-05 | $2.38M 10-Q · filed 2025-11-05 | $2.34M 10-Q · filed 2024-11-07 | $3.14M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $788.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.55M 10-Q · filed 2025-08-05 | $1.53M 10-Q · filed 2024-08-08 | $2.31M derived: sum of 3 quarters · filed 2026-02-26 | $3.06M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $764.00K 10-Q · filed 2025-05-07 | $1.53M derived: sum of 2 quarters · filed 2026-02-26 | $2.27M derived: sum of 3 quarters · filed 2026-02-26 | $3.02M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $762.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.51M derived: sum of 2 quarters · filed 2026-02-26 | $2.25M derived: sum of 3 quarters · filed 2026-02-26 | $3.00M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $746.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.49M derived: sum of 2 quarters · filed 2024-11-07 | $2.24M 10-Q · filed 2024-11-07 | $2.98M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.49M 10-Q · filed 2024-08-08 | $2.23M derived: sum of 3 quarters · filed 2024-08-08 | $2.92M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $746.00K 10-Q · filed 2024-05-10 | $1.49M derived: sum of 2 quarters · filed 2024-05-10 | $2.17M derived: sum of 3 quarters · filed 2024-05-10 | $2.82M derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | $743.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.42M derived: sum of 2 quarters · filed 2024-03-27 | $2.08M derived: sum of 3 quarters · filed 2024-03-27 | $2.73M 10-K · filed 2024-03-27 | ||
| 2022-09-30 | $680.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.33M derived: sum of 2 quarters · filed 2023-11-09 | $1.99M 10-Q · filed 2023-11-09 | $1.99M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $655.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.31M 10-Q · filed 2023-08-10 | $1.31M derived: sum of 3 quarters · filed 2023-08-10 | $1.31M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $656.00K 10-Q · filed 2023-05-11 | $656.00K derived: sum of 2 quarters · filed 2023-05-11 | $656.00K derived: sum of 3 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |